Ann: Long COVID study identifies diagnostic & therapeutic targets, page-2

Of the 94.7 million people in the US diagnosed as infected and surviving COVID-193, approximately 82
million (87%) people are non-hospitalized4, and 45% of non-hospitalized patients5 have developed some
manifestation of Long COVID-19 syndrome which suggests more than 24 million people are afflicted by the
condition to some extent. The main neurological symptom is brain fog (defined with the established memory
tests conducted) and reported in 81% suggesting an impact on nearly 20 million people in the US.
______________________________________________________________________________________________________ LEVEL 1, 14 WALLACE AVENUE, TOORAK VIC 3142 AUSTRALIA TEL . +61 (3) 9827 8999 FAX +61 3 9859 7701 WEB WWW.ANTISENSE.COM.AU
ANTISENSE THERAPEUTICS LIMITED ABN 41 095 060 745
Identification of appropriate biomarkers of Long COVID-19 have proved elusive.
6 The National Institute of
Health (NIH) in the US is funding a national research effort focused on understanding and treating Long
COVID-19 beyond US$1billion it has already committed.
7
One of the aims of the proteomics analysis was to assess if Neuro Long COVID-19 patients may have been
amendable to treatment with ANP’s immunomodulatory drug ATL1102 which has previously demonstrated
biologic activity in MS patients11 and the ability to reduce T cells and modulate proteins involved in the
blood of DMD patients (data presented at the 2021 World Muscle Society conference WMS-ATL1102-DMDPROTEOMICS-Poster). Encouragingly, one of the potential therapeutic markers in Long COVID-19 patients
identified from this proteomics analysis is also known as having the potential to be significantly modulated
by ATL1102 in DMD patients and therefore is suggestive of its therapeutic potential in Long COVID-19. The
Company is looking to further explore the clinical potential of ATL1102 in this setting via applying for grant
funding opportunities (such as that as offered by NIH) in collaboration with Professor Koralnik.
Dr Koralnik said, “The collaboration with Antisense Therapeutics has generated promising novel data in
Long COVID-19 patients in identifying potential disease biomarkers and represents an important advance
towards the goal of establishing effective disease diagnostics and interventional treatments. We look
forward to continuing our scientific collaboration with Antisense Therapeutics and to advancing such
endeavors through our active involvement and support in seeking grant applications including with bodies
such as the NIH.


The above is worth a read a few times.